GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elutia Inc (NAS:ELUT) » Definitions » EBIT

Elutia (Elutia) EBIT : $-36.28 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Elutia EBIT?

Elutia's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-13.72 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-36.28 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Elutia's annualized ROC % for the quarter that ended in Dec. 2023 was -52.48%. Elutia's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -13,159.71%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Elutia's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -49.80%.


Elutia EBIT Historical Data

The historical data trend for Elutia's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elutia EBIT Chart

Elutia Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -6.53 -16.17 -19.45 -31.03 -35.43

Elutia Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.57 -6.42 -9.09 -7.06 -13.72

Competitive Comparison of Elutia's EBIT

For the Medical Devices subindustry, Elutia's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elutia's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Elutia's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Elutia's EV-to-EBIT falls into.



Elutia EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elutia  (NAS:ELUT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Elutia's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-23.188 * ( 1 - 0.05% )/( (45.797 + 42.536)/ 2 )
=-23.176406/44.1665
=-52.48 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Elutia's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-54.876/( ( (0.33 + max(-27.179, 0)) + (0.504 + max(-30.16, 0)) )/ 2 )
=-54.876/( ( 0.33 + 0.504 )/ 2 )
=-54.876/0.417
=-13,159.71 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.883 + 6.503 + 7.772) - (14.392 + 0 + 29.945)
=-27.179

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.263 + 3.853 + 2.165) - (12.676 + 0 + 26.765)
=-30.16

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Elutia's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-36.281/72.856
=-49.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elutia EBIT Related Terms

Thank you for viewing the detailed overview of Elutia's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Elutia (Elutia) Business Description

Traded in Other Exchanges
N/A
Address
12510 Prosperity Drive, Suite 370, Silver Spring, MD, USA, 20904
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health, Orthobiologics, and Cardiovascular. It generates maximum revenue from the Orthobiologics segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Executives
Elutia Pipe Investment, Lp 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Birchview Fund Llc 10 percent owner 688 PINE STREET, BURLINGTON VT 05401
Thomas Englese officer: Chief Commercial Officer C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRING MD 20904
David Colpman director 452 FIFTH AVENUE, NEW YORK NY 10018
Brigid Makes director 20245 SW 95TH AVENUE, TUALATIN OR 97062
Matthew Ferguson officer: Chief Financial Officer C/O FOXHOLLOW TECHNOLOGIES, INC., 740 BAY ROAD, REDWOOD CITY CA 94063
Highcape Partners Gp Ii, Llc 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Gp Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Qp Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Capital, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Michelle Leroux Williams officer: Chief Scientific Officer C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRINT MD 20904
Matthew Strobeck 10 percent owner C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Birchview Capital, Lp 10 percent owner 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON VT 05401
Peter G Edwards officer: GENERAL COUNSEL C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015